Sunday, 23 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com

VALNEVA Stock Went Up By Over 9% So Far On Tuesday

Loading stream...

(vianews) - shares of valneva (cac 40: vla.pa) rose 9.64% to €7.44 at 14:08 est on tuesday, following the last session's upward trend. cac 40 is falling 0.19% to €7,300.12, following the last session's downward trend. this seems, up until now, a somewhat negative trend trading session today.

about valneva

valneva se, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. it offers ixiaro, an inactivated vero cell culture-derived japanese encephalitis vaccine indicated for active immunization against japanese encephalitis; dukoral, an oral vaccine for the prevention of diarrhea caused by vibrio cholera and/or heat-labile toxin producing enterotoxigenic escherichia coli bacterium; and vla2001, an inactivated whole-virus covid-19 vaccine. the company also develops vla15, a vaccine candidate, which is in phase iii clinical trial against borrelia, the bacterium that causes lyme disease; vla1553, a vaccine candidate, which is in phase iii clinical trial against the chikungunya virus; vla1554, a vaccine candidate targeting human metapneumovirus; and vla2112, a vaccine candidate to treat patients with epstein-barr virus. it sells its products in the united states, canada, germany, austria, nordics, the united kingdom, france, rest of european countries, and internationally. valneva se has collaborations with pfizer, inc. to co-develop and commercialize its lyme disease vaccine; and instituto butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. the company was founded in 1998 and is based in saint-herblain, france.

earnings per share

as for profitability, valneva has a trailing twelve months eps of €-1.13.

volatility

valneva's last week, last month's, and last quarter's current intraday variation average was 2.78%, 1.01%, and 2.85%.

valneva's highest amplitude of average volatility was 2.88% (last week), 2.68% (last month), and 2.85% (last quarter).

volume

today's last reported volume for valneva is 1329669 which is 241.29% above its average volume of 389601.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, valneva's stock is considered to be oversold (<=20).

more news about valneva (vla.pa).

In this story · Knowledge Files